TW202000701A - Bcma結合抗體及其用途 - Google Patents

Bcma結合抗體及其用途 Download PDF

Info

Publication number
TW202000701A
TW202000701A TW108105895A TW108105895A TW202000701A TW 202000701 A TW202000701 A TW 202000701A TW 108105895 A TW108105895 A TW 108105895A TW 108105895 A TW108105895 A TW 108105895A TW 202000701 A TW202000701 A TW 202000701A
Authority
TW
Taiwan
Prior art keywords
seq
bcma
antibody
cell
polypeptide
Prior art date
Application number
TW108105895A
Other languages
English (en)
Chinese (zh)
Inventor
馬漢 阿巴森
顯理 陳
坎德薩米 哈里哈蘭
廷勳 宣
安德魯 烏姆瑟爾
Original Assignee
美商西建公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西建公司 filed Critical 美商西建公司
Publication of TW202000701A publication Critical patent/TW202000701A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW108105895A 2018-02-21 2019-02-21 Bcma結合抗體及其用途 TW202000701A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633152P 2018-02-21 2018-02-21
US62/633,152 2018-02-21

Publications (1)

Publication Number Publication Date
TW202000701A true TW202000701A (zh) 2020-01-01

Family

ID=65686040

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108105895A TW202000701A (zh) 2018-02-21 2019-02-21 Bcma結合抗體及其用途

Country Status (15)

Country Link
US (2) US11401336B2 (enExample)
EP (1) EP3755718A1 (enExample)
JP (1) JP2021514193A (enExample)
KR (1) KR20200123155A (enExample)
CN (1) CN112272675A (enExample)
AR (1) AR115257A1 (enExample)
AU (1) AU2019223076A1 (enExample)
BR (1) BR112020017053A2 (enExample)
CA (1) CA3092037A1 (enExample)
EA (1) EA202091974A1 (enExample)
IL (1) IL276548A (enExample)
MX (1) MX2020008718A (enExample)
SG (1) SG11202007495SA (enExample)
TW (1) TW202000701A (enExample)
WO (1) WO2019164891A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005983A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
AU2021263408A1 (en) * 2020-04-30 2022-10-27 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
CN118159563A (zh) * 2021-10-27 2024-06-07 詹森生物科技公司 用于人和猴组织中的增强型bcma免疫组织化学检测的方法
US12692314B2 (en) * 2022-05-06 2026-07-28 IGI Therapeutics SA CD3/BCMA/CD38 trispecific antibodies
PY2342675A (es) * 2022-06-09 2023-12-11 Biocad Joint Stock Co Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a bcma, y uso del mismo
WO2025184567A1 (en) * 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
WO2026072709A1 (en) 2024-09-25 2026-04-02 Orna Therapeutics, Inc. Chimeric antigen receptors targeting bcma

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5763477A (en) 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
AU5305796A (en) 1995-03-10 1996-10-02 Hauser Chemical Research, Inc. Cephalomannine epoxide, its analogues and a method for preparing the same
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
DE69740140D1 (de) 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
FI990180A7 (fi) 1996-08-12 1999-03-08 Celgene Corp Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101500T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
WO2000055134A1 (en) 1999-03-18 2000-09-21 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
AU2005311888A1 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
BRPI0607239A2 (pt) 2005-01-25 2009-08-25 Celgene Corp usos de uma quantidade terapeuticamente ou profilaticamente eficaz de 4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol-1,3-d iona, de (3r)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, e de (3s)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, ou um sal ou solvato farmaceuticamente aceitável das mesmas, composição farmacêutica, e, forma de dosagem unitária simples
CA2822094C (en) 2005-08-31 2015-10-27 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
WO2010032061A1 (en) * 2008-09-19 2010-03-25 Medimmune Llc Antibodies against sonic hedgehog homolog and uses thereof
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
RU2611007C2 (ru) 2011-03-11 2017-02-17 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
BR112016024546A2 (pt) * 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
AU2015292744C1 (en) * 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
JP6901493B2 (ja) * 2015-11-13 2021-07-14 アメリカ合衆国 抗ｂｃｍａポリペプチド及びタンパク質
NZ746700A (en) * 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
IL299221A (en) * 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies

Also Published As

Publication number Publication date
AU2019223076A1 (en) 2020-10-08
WO2019164891A1 (en) 2019-08-29
EA202091974A1 (ru) 2020-12-08
IL276548A (en) 2020-09-30
MX2020008718A (es) 2020-12-07
US20220324991A1 (en) 2022-10-13
KR20200123155A (ko) 2020-10-28
WO2019164891A9 (en) 2020-09-17
CN112272675A (zh) 2021-01-26
AR115257A1 (es) 2020-12-16
EP3755718A1 (en) 2020-12-30
BR112020017053A2 (pt) 2020-12-15
CA3092037A1 (en) 2019-08-29
JP2021514193A (ja) 2021-06-10
US11401336B2 (en) 2022-08-02
SG11202007495SA (en) 2020-09-29
US20200399386A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
US20220324991A1 (en) Bcma-binding antibodies and uses thereof
JP7605912B2 (ja) Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
CA2851814C (en) Antibody polypeptides that antagonize cd40l
US20210038646A1 (en) Chimeric antigen receptors targeting the tumor microenvironment
TW202110873A (zh) 嵌合受體及其使用方法
TW202043280A (zh) 對受體酪胺酸激酶樣孤兒受體１（ｒｏｒ１）具專一性之抗體及嵌合抗原受體
CN110267677A (zh) 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
KR20170128234A (ko) Ror1에 특이적인 항체 및 키메라 항원 수용체
EP4442701A1 (en) Combination of molecular switch regulation type chimeric antigen receptor cell and antibody, and use thereof
CN117715935A (zh) 抗cd33抗体及其用途
KR20230015348A (ko) Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물
CN117693528A (zh) 抗cll1抗体及其构建体
EA044652B1 (ru) Связывающие bcma антитела и их применение
WO2026001894A1 (zh) 靶向axl的嵌合抗原受体及其用途
KR20250135354A (ko) Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도
HK40108858A (en) Antibodies against cll1 and constructs thereof
JP2026508096A (ja) 治療抗体
EA052847B1 (ru) Химерные антигенные рецепторы gprc5d и экспрессирующие их клетки